CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Items 301–400 of 661
Manna, M. P. L., Liberto, D. D., Pizzo, M. L., Mohammadnezhad, L., Azgomi, M. S., Salamone, V., Cancila, V., Vacca, D., Dieli, C., Maugeri, R., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10102454 · Cited by 25
Jiang, M., Fiering, S., & Shao, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153066 · Cited by 23
Talhouni, S., Fadhil, W., Mongan, N. P., Field, L., Hunter, K. J., Makhsous, S., Maciel-Guerra, A., Kaur, N., Nestarenkaitė, A., Laurinavičius, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1057292 · Cited by 24
“The presence of CD103 TIL in ovarian (26, 27), breast (26) lung (23, 28) and head and neck cancers (21) has shown a stronger correlation with survival than canonical T-cell markers such as CD3 or CD8.”
BackgroundAbascal, J. W., Oh, M. S., Liclican, E. L., Dubinett, S. M., Salehi‐Rad, R., & Liu, B. (2023) · Cells · doi:10.3390/cells12192404 · Cited by 26
“effector functions, is associated with enhanced survival in patients with lung cancer [39].”
Intratumoral antigen signaling traps CD8 + T cells to confine exhaustion to the tumor site
Takahashi, M., So, T. Y., Chamberlain-Evans, V., Hughes, R., Yam‐Puc, J. C., Kania, K., Ruhle, M., Mann, T., Schuijs, M. J., Coupland, P. G., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade2094 · Cited by 26
“These findings corroborate reports of exhausted T cells expressing CD103 (a key protein in T cell residency) (10, 11), and reports of tumor-reactive cells being largely confined to the tumor (12, 13).”
Advancing non-small cell lung cancer treatment: the power of combination immunotherapies
Wu, Y., Yu, G., Jin, K., & Qian, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1349502 · Cited by 28
Onion, D., Isherwood, M., Shridhar, N., Xenophontos, M., Craze, M. L., Day, L. J., Garcia-Marquez, M. A., Pineda, R. G., Reece-Smith, A. M., Saunders, J. H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18880 · Cited by 23
“com/oncotarget phenotype (TRM) also includes up-regulation of checkpoint proteins including PD-1, rationalising the efficacy of PD-1 inhibitor trials and supported by in vitro tumour cell killing by CD8+ CD103+ cells when under PD-1 blockade [16].”
BackgroundInfluentialA Task Force Against Local Inflammation and Cancer: Lymphocyte Trafficking to and Within the Skin
Lafouresse, F., & Groom, J. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02454 · Cited by 23
Chen, F., Yang, Y., Zhao, Y., Pei, L., & Yan, H. (2019) · DNA and Cell Biology · doi:10.1089/dna.2019.4899 · Cited by 26
“A recent finding on the role of CD8 + CD103 + tissue-resident memory T cells in NSCLC also supported the use of anti-PD-1 blocking Ab in reversing the tumor-induced T cell exhaustion in NSCLC patients and prolonged survival (Djenidi et al. , 2015).”
Wang, J., Shi, W., Miao, Y., Gan, J., Guan, Q., & Ran, J. (2021) · Bioengineered · doi:10.1080/21655979.2021.1971029 · Cited by 23
“EGFR (epidermal growth factor receptor) mutations or ALK (anaplastic lymphoma kinase) rearrangements in NSCLC usually exhibit poor clinical benefits to checkpoint inhibitor (CPI) [20,21], although few reports have explained the underlying mechanism.”
BackgroundInfluentialGitto, S., Natalini, A., Antonangeli, F., & Rosa, F. D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755304 · Cited by 23
“In one of these studies, a positive response of NSCLC patients to anti-PD-1/PD-L1 therapy was correlated to an increased intratumoral density of CD8 CD103 TILs, which displayed typical transcriptomic and phenotypic profiles of TRM (83).”
BackgroundIsomoto, K., Haratani, K., Tsujikawa, T., Makutani, Y., Kawakami, H., Takeda, M., Yonesaka, K., Tanaka, K., Iwasa, T., Hayashi, H., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.10.012 · Cited by 23
CD39 Is Expressed on Functional Effector and Tissue-resident Memory CD8+ T Cells
Isaacs, J. F., Degefu, H. N., Chen, T., Kleist, S. A., Musial, S. C., Ford, M. A., Searles, T. G., Lin, C., Skorput, A. G. J., Shirai, K., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400151 · Cited by 23
Cellular heterogeneity and key subsets of tissue-resident memory T cells in cervical cancer
Wang, F., Yue, S., Huang, Q., Lei, T., Li, X., Wang, C., Yue, J., & Liu, C. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00637-3 · Cited by 22
CD8-positive memory T cells in tumor-draining lymph nodes of patients with breast cancer
Vahidi, Y., Bagheri, M., Ghaderi, A. A., & Faghih, Z. S. (2020) · BMC Cancer · doi:10.1186/s12885-020-6714-x · Cited by 25
Park, M. H., Kwon, S. Y., Choi, J. E., Gong, G., & Bae, Y. K. (2020) · Histopathology · doi:10.1111/his.14126 · Cited by 24
“Moreover some CD103CD8 TILs expressed programmed cell death 1 (PD)-1, a T cell exhaustion marker, in ovarian and lung cancer.(19,22,34) We believe that not all CD103CD8 cells are anti-tumour effector cells, but rather that some are functionally exhausted as a consequence of chronic antigenic stimulation.”
BackgroundResultHolding our breath: the promise of tissue-resident memory T cells in lung cancer
Marceaux, C., Weeden, C. E., Gordon, C. L., & Asselin-Labat, M.-L. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-819 · Cited by 22
“High numbers of tumor infiltrating lymphocytes (TILs) that display a CD103 TRM-like phenotype in carcinomas have been associated with improved survival in multiple solid cancers (7-9).”
InfluentialFunctional Heterogeneity and Therapeutic Targeting of Tissue-Resident Memory T Cells
van der Gracht, E. T. I., Behr, F. M., & Arens, R. (2021) · Cells · doi:10.3390/cells10010164 · Cited by 25
“In non-small cell lung carcinoma, tumor-specific CD103+CD8+ TILs, expressing PD-1 and Tim-3, constitute a highly activated subpopulation and represent a prognostic factor for survival [42].”
BackgroundWei, J., Fang, D., & Zhou, W. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3301 · Cited by 22
Ida, S., Takahashi, H., Kawabata‐Iwakawa, R., Mito, I., Tada, H., & Chikamatsu, K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105508 · Cited by 22
Damei, I., Caidi, A., Auclin, É., Adam, J., Mella, S., Hasan, M., Tartour, É., Robert, C., Corgnac, S., & Mami‐Chouaib, F. (2025) · Nature Communications · doi:10.1038/s41467-025-60657-w · Cited by 23
“It is widely accepted that a lineage of CD8 memory T cells known astissue-residentmemoryT(T RM )cells,ispresentinsomehumansolid tumoursandisassociatedwithafavourableprognosisandresponseto PD-1 blockade 12 – 20 .”
Self-citationAtlas-guided discovery of transcription factors for T cell programming
Chung, H. K., Liu, C., Battu, A., Jambor, A. N., Pratt, B. M., Xie, F., Riesenberg, B., Casillas, E., Sun, M., Landoni, E., et al. (2026) · Nature · doi:10.1038/s41586-025-09989-7 · Cited by 27
Mazzoni, A., Maggi, L., Montaini, G., Ramazzotti, M., Capone, M., Vanni, A., Locatello, L. G., Barra, G., Palma, R. D., Gallo, O., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048544 · Cited by 22
The role of lymphocyte-monocyte ratio on axial spondyloarthritis diagnosis and sacroiliitis staging
Wang, J., Su, J., Yuan, Y., Jin, X., Shen, B., & Lu, G. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-03973-8 · Cited by 21
Akanda, Z. Z., Neeson, P. J., John, T., Barnett, S. A., Hanna, G. G., Miller, A., Jennens, R. R., & Siva, S. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1117 · Cited by 22
Amelioration of NK cell function driven by Vα24 + invariant NKT cell activation in multiple myeloma
Iyoda, T., Yamasaki, S., Hidaka, M., Kawano, F., Abe, Y., Suzuki, K., Kadowaki, N., Shimizu, K., & Fujii, S. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.10.007 · Cited by 21
Decoding Tissue-Residency: Programming and Potential of Frontline Memory T Cells
Park, S. L., & Mackay, L. K. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a037960 · Cited by 21
Mittra, S., Harding, S. M., & Kaech, S. M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300049 · Cited by 21
Interaction between gut microbiota and T cell immunity in colorectal cancer
Jing, Z., Wu, Y., Chu, J., Zhanbo, Q., Wu, X., & Han, S. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103807 · Cited by 20
Tissue‐resident and memory properties of human T‐cell and NK‐cell subsets
Lugli, E., Hudspeth, K. L., Roberto, A., & Mavilio, D. (2016) · European Journal of Immunology · doi:10.1002/eji.201545702 · Cited by 22
Workel, H. H., van Rooij, N., Plat, A., Spierings, D. C. J., Fehrmann, R. S. N., Nijman, H. W., & de Bruyn, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113770 · Cited by 20
Tissue‐resident memory T cells in diseases and therapeutic strategies
Xie, D., Lu, G., Mai, G., Guo, Q., & Xu, G. (2025) · MedComm · doi:10.1002/mco2.70053 · Cited by 21
The Roles and Mechanisms of TRAT1 in the Progression of Non-Small Cell Lung Cancer
Guo, Q., Wang, S.-H., Ji, Y., Tong, S., Li, D., Ding, X., & Wu, C. (2022) · Current Medical Science · doi:10.1007/s11596-022-2625-1 · Cited by 20
CAO, H., XUE, Y., Wang, F., LI, G., Zhen, Y., & GUO, J. (2024) · Biocell · doi:10.32604/biocell.2024.048946 · Cited by 19
Ruocco, M. R., Gisonna, A., Acampora, V., D'Agostino, A. G., Carrese, B., Santoro, J., Venuta, A., Nasso, R., Rocco, N., Russo, D., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116224 · Cited by 22
Respiratory delivered vaccines: Current status and perspectives in rational formulation design
Wu, L., Xu, W., Jiang, H., Yang, M., & Cun, D. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.08.026 · Cited by 20
Chen, P., Ming, S., Lao, J., Li, C., Wang, H., Xiong, L., Zhang, S.-X., Liang, Z., Niu, X., Deng, S., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00436 · Cited by 19
“AntiCD103 neutralizing monoclonal antibodies compromise the cytotoxic function of CD103 tumor-infiltrating lymphocytes (TILs) to kill autologous tumor cells (Djenidi et al., 2015).”
BackgroundSanders, C., Hamad, A. S. M., Ng, S. S., Hosni, R., Ellinger, J., Klümper, N., Ritter, M., Stephan, C., Jung, K., Hölzel, M., et al. (2022) · Cancers · doi:10.3390/cancers14061541 · Cited by 18
“An accumulation of tissue-resident memory CD103+ T-lymphocytes has been associated with a better prognosis in head and neck tumors [8] and lung cancer [9].”
BackgroundHan, Y., Ju, W., Ji, R., Tan, H. Y., Tian, S., Yin, J., Xu, J., Chen, X., Liu, W., & Cui, H. (2023) · BMC Cancer · doi:10.1186/s12885-023-11251-0 · Cited by 19
“Additionally, several subtypes of tumor-infiltrating lymphocytes have been associated with improved prognosis in various malignancies [47], including CD8 + T cells [19] and memory T cells [48].”
BackgroundGorchs, L., Moro, C. F., Asplund, E., Oosthoek, M., Solders, M., Ghorbani, P., Sparrelid, E., Rangelova, E. B., Löhr, M. J., & Kaipe, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0405 · Cited by 19
Jiang, C., Chao, C., Li, J., Ge, X., Shen, A., Jucaud, V., Cheng, C., & Shen, X. (2024) · iScience · doi:10.1016/j.isci.2024.109277 · Cited by 19
“3,8,11 A systematic study examining all available patient scRNA-seq and bulk RNA-seq data to comprehensively assess the impact of T RM on the remaining immune cells in the tumor milieu and to extract T RM -related molecular signatures that can provide prognostic value in clinical settings have been…”
BackgroundOltmanns, F., Antão, A. V., Irrgang, P., Viherlehto, V., Jörg, L., Schmidt, A. P., Wagner, J. T., Rückert, M., Flohr, A.-S., Geppert, C. I., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008652 · Cited by 18
“However, it should be noted that the survival rate of mucosally vaccinated animals was lower and the mean survival time shorter on FTY720 treatment compared with the previous experiment (figure 3D,E).”
Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC
Chen, Y., Shao, Z., Hao, Z., Xin, Z., Chen, X., Lijian, H., Chen, D., Lin, M., Liu, Q., Xu, X., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007854 · Cited by 19
Dhodapkar, K. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01655 · Cited by 19
“In recent studies, we and others have shown that TRM cells are the dominant T cell subset expressing ICPs within the tumor microenvironment (11, 25).”
BackgroundResultMelssen, M. M., Olson, W. C., Wages, N. A., Capaldo, B. J., Mauldin, I. S., Mahmutovic, A., Hutchison, C., Melief, C. J. M., Bullock, T. N. J., Engelhard, V. H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1490855 · Cited by 19
“The presence of CD103 or CD49a TILs in the tumor microenvironment (TME) is associated with improved survival in several types of cancer, suggesting CD49a and CD103 may support retention, survival or effector function of T cells in the TME, or that theymay mark a T cell subset more effective in anti-tumor immunity.(15-…”
BackgroundPrognostic Value of SLC4A4 and its Correlation with Immune Infiltration in Colon Adenocarcinoma
Chen, X., Chen, J., Yan, F., & Guan, W. (2020) · Medical Science Monitor · doi:10.12659/msm.925016 · Cited by 20
Development of a gene signature associated with iron metabolism in lung adenocarcinoma
Qin, J., Xu, Z., Deng, K., Qin, F., Wei, J., Yuan, L., Sun, Y., Zheng, T., & Li, S. (2021) · Bioengineered · doi:10.1080/21655979.2021.1954840 · Cited by 21
“Previous research has indicated that CD8 + T cells [43,44] and macrophages [44,45] have a connection with the poor prognosis of lung cancer patients.”
ResultFung, K. Y., Nguyen, P. M., & Putoczki, T. L. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.11.013 · Cited by 18
Donkor, M., Choe, J. Y., Reid, D. M., Quinn, B., Pulse, M., Ranjan, A. P., Chaudhary, P., & Jones, H. P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020445 · Cited by 17
Tissue-Resident Memory T Cell: Ontogenetic Cellular Mechanism and Clinical Translation
Xu, H., Zhou, R., & Chen, Z. (2023) · Clinical & Experimental Immunology · doi:10.1093/cei/uxad090 · Cited by 17
Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System
Cerullo, V., Capasso, C., Vähä-Koskela, M. J. V., Hemminki, O., & Hemminki, A. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009617666170502152352 · Cited by 18
The toxicity of cell therapy: Mechanism, manifestations, and challenges
Jin, Y., Dong, Y., Jin, Z., Sun, J., Liu, Y., & Chen, Y. (2020) · Journal of Applied Toxicology · doi:10.1002/jat.4100 · Cited by 21
“TILs have shown antitumor activity in various cancer types, such as melanoma (Rosenberg et al., 1988; Rosenberg et al., 2011), lung cancer (Djenidi et al., 2015), and gastrointestinal cancers (Tran et al., 2015).”
BackgroundTargeting Neoepitopes to Treat Solid Malignancies: Immunosurgery
de Sousa, E., Lérias, J. R., López-Beltrán, A., Paraschoudi, G., Condeço, C., Kamiki, J., António, P., Figueiredo, N., Carvalho, C. T., Castillo-Martín, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.592031 · Cited by 19
Advancements in the characterization of tissue resident memory T cells in skin disease
Li, L., Liu, P., Chen, C., Yan, B., Chen, X. '., Li, J., & Peng, C. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109183 · Cited by 19
Vigil: Personalized Immunotherapy Generating Systemic Cytotoxic T Cell Response
Herron, J. N., Smith, N., Stanbery, L., Aaron, P. A., Manning, L., Bognar, E., Wallraven, G., Horvath, S., & Nemunaitis, J. J. (2020) · Cancer Science & Research · doi:10.33425/2639-8478.1055 · Cited by 16
“CD8+ cytotoxic T lymphocytes (CTLs) also play a key role in CMI and are predictive of improved clinical outcomes in many solid tumors [2-9].”
BackgroundXu, L., Ye, L., & Huang, Q. (2025) · MedComm · doi:10.1002/mco2.70132 · Cited by 18
The Emerging Role of Tissue-Resident Memory CD8+ T Lymphocytes in Human Digestive Tract Cancers
Mei, X., Li, H., Zhou, X., Cheng, M., & Cui, K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.819505 · Cited by 18
Immunotherapeutic Approaches for Glioblastoma Treatment
Yaghi, N. K., & Gilbert, M. R. (2022) · Biomedicines · doi:10.3390/biomedicines10020427 · Cited by 16
Kuo, C.-H. S., Liu, C., Pavlidis, S. P., Lo, Y.-L., Wang, Y., Chen, C., Ko, H., Chung, F., Lin, T.-Y., Wang, T., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00232 · Cited by 16
Aoki, T., Nishida, N., & Kudo, M. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211056853 · Cited by 15
ONUMA, S., HASHIMOTO, I., Suematsu, H., Nagasawa, S., KANEMATSU, K., Aoyama, T., Yamada, T., Rino, Y., Ogata, T., & Oshima, T. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030432 · Cited by 15
“Lymphocytes, particularly CD8+ T cells [44,45] and memory T cells [46], play a crucial role in antitumor immune function and inhibit the progression of several cancers.”
BackgroundHashimoto, M., Kuroda, S., Kanaya, N., Kadowaki, D., Yoshida, Y., Sakamoto, M., Hamada, Y., Sugimoto, R., Yagi, C., Ohtani, T., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02583-0 · Cited by 15
Yang, L., Yang, H., Zhao, M., Yuan, H., Geng, J., Yan, Y., Li, W., Xing, L., Yu, J., & Sun, X. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00831-x · Cited by 17
“Conversely, the densities of CD8 + T RM1 and CD8 + T RM2 subsets did not exhibitstatisticallysigni fi cantdifferences(CD8 + T RM1 :13[8,25]vs11[5,21], P = 0.059; CD8 + T RM2 : 2 [1,4] vs 3 [1,6], P = 0.285) (Fig.”
InfluentialQi, J., Liu, X., Yan, P., He, S., Lin, Y., Huang, Z., Zhang, S., Xie, S., Li, Y., Lü, X., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.724232 · Cited by 16
“Previous studies have confirmed that CD4 GzmB T cells were involved in the antitumor immune response of bladder cancer (59), non-small cell lung cancer (60), and colorectal cancer (61).”
ResultThe application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment
Shi, M.-Y., Liu, H.-G., Chen, X.-H., Tian, Y., Chen, Z., & Wang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1088886 · Cited by 15
Tim-3: Biomarqueur et cible thérapeutique en cancérologie
Granier, C., Gey, A., Dariane, C., Méjean, A., Timsit, M., Blanc, C., Verkarre, V., Radulescu, C., Fabre, E., Vano, Y. A., et al. (2018) · médecine/sciences · doi:10.1051/medsci/20183403011 · Cited by 16
Vlaming, M. R., Bilemjian, V., Freile, J. Á., Melo, V. A., Plat, A., Huls, G. A., Nijman, H. W., de Bruyn, M., & Bremer, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1031746 · Cited by 15
Witzleben, A. V., Ellis, M. J., Thomas, G. J., Hoffmann, T. K., Jackson, R., Laban, S. A., & Ottensmeier, C. H. H. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0445 · Cited by 16
Min, J., Dong, F., Chen, Y., Li, W., Wu, Y., Tan, Y., Yang, F., Wu, P., & Chai, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379812 · Cited by 18
Tao, Y., Wang, G., Zhai, J., & Zhang, N. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106023 · Cited by 14
Legend of the Sentinels: Development of Lung Resident Memory T Cells and Their Roles in Diseases
Qian, Y., Zhu, Y., Li, Y., & Li, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624411 · Cited by 18
“These lung tumor TRM cells predict a better survival outcome in early-stage non-small-cell lung carcinoma (NSCLC) patients, as well as increased intraepithelial lymphocyte infiltration (68).”
BackgroundCD4+ follicular helper-like T cells are key players in anti-tumor immunityPreprint
Singh, D., Ganesan, A. P., Panwar, B., Eschweiler, S., Hanley, C. J., Madrigal, A., Ramírez-Suástegui, C., Wang, A., Clarke, J., Wood, O., et al. (2020) · ePrints Soton (University of Southampton) · doi:10.1101/2020.01.08.898346 · Cited by 6
“The primary antibodies used for IHC includes anti-CD103 (EPR4166(2); 1:500; Abcam), anti-CXCL13 (polyclonal; 1:100; ThermoFisher Scientific), anti-CD8 (C8/144B; pre-diluted; Agilent Dako), anti-CD4 (4B12; pre-diluted; Agilent Dako), anti-granzyme B (GrB-7; 1:50; Dako) and antiPanCK (AE1/AE3; pre-diluted; Agilent Dako).”
BackgroundPotential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy
Wu, G., Dong, Y., Deng, Y. L., Chen, L., Chen, J., Liu, M., Wu, J., Wang, W., & Ma, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1003626 · Cited by 13
“1) Melanoma and Metastatic melanoma 2) NSCLC 3) colorectal cancer and CRLM 4) Gastrointestinal cancer 5) Renal cell carcinoma 6) Mouse tumor cell lines(B16-OVA、 MC38、ID8、5TGM1) Melanoma Colon Cancer Myeloma Multiforme NCT00937625 (MM) NCT03215810 (16, 21–24, 26–29) CD39+CD8+ T cells • Enriched in expression of genes r…”
BackgroundInfluentialBaudouin, R., Hans, S., Lisan, Q., Morin, B., Adimi, Y., Martin, J., Lechien, J. R., Tartour, É., & Badoual, C. (2023) · The Laryngoscope · doi:10.1002/lary.31010 · Cited by 17
Roles of tissue-resident immune cells in immunotherapy of non-small cell lung cancer
Tang, R., Wang, H., & Tang, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1332814 · Cited by 15
Aquino, A., & Franzese, O. (2025) · Cancers · doi:10.3390/cancers17091547 · Cited by 13
Archetypes of checkpoint-responsive immunity
Im, K. W., Combes, A. J., Spitzer, M. H., Satpathy, A. T., & Krummel, M. F. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.007 · Cited by 15
“with deep sequencing (ATAC-seq) analysis revealed that the epigenetic profiles of TEX cells were distinct from those of CD8+ Teff and CD8+ memory T cells in lung cancer patients [72].”
MethodResultSolid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells
Sullivan, P. M., Reed, S. J., Kalia, V., & Sarkar, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.706150 · Cited by 13
“These findings are consistent with similar reports in distinct murine and human tumors as well (19, 20, 24, 52).”
ResultGomez‐Roca, C., Michelas, M., Scarlata, C., Salvioni, A., Gomez‐Roca, C., Sarradin, V., Lauzéral-Vizcaïno, F., Féliu, V., Dupret‐Bories, A., Ferron, G., et al. (2022) · Cancers · doi:10.3390/cancers14153679 · Cited by 14
“Terminally exhausted tumor-infiltrating CD8 T cells express tissue resident memory T-cell (Trm) markers, which allow for their retention at the tumor site [4,27,28].”
BackgroundClonal expansion of intra‐epithelial T cells in breast cancer revealed by spatial transcriptomics
Romanens, L., Chaskar, P., Marcone, R., Ryser, S., Tille, J., Genolet, R., Hu, K., Heimgartner, K., Moore, J. S., Liaudet, N., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34620 · Cited by 13
“Conceptually, these intraepithelial TILs have always been there (meaning that not all immigrate from the systemic circulation) and are likely tumor antigen-specific, promoting a favorable clinical outcome.(33,34) While the milder association with anti-tumor effects, and the high diversity/low clonality of the TCR repe…”
BackgroundConsiderations on the Design of Lipid-based mRNA Vaccines Against Cancer
Meulewaeter, S., Zhang, Y., Wadhwa, A., Fox, K., Lentacker, I., Harder, K. W., Cullis, P. R., Smedt, S. C. D., Cheng, M. H. Y., & Verbeke, R. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168385 · Cited by 13
Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer
Hynes, C. F., Kwon, D. H., Vadlamudi, C., Lofthus, A., Iwamoto, A., Chahine, J. J., Desale, S. Y., Margolis, M., Kallakury, B., Watson, T. J., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.05.002 · Cited by 13
Accumulation of CD103+ CD8+ T cells in a cutaneous melanoma micrometastasis
Hochheiser, K., Yeang, H. X. A., Wagner, T., Tutuka, C. S. A., Behren, A., Waithman, J. C., Angel, C. M., Neeson, P. J., Gebhardt, T., & Gyorki, D. E. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1100 · Cited by 13
Discipline in Stages: Regulating CD8+ Resident Memory T Cells
Mora‐Buch, R., & Bromley, S. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.624199 · Cited by 16
PLGA particle vaccination elicits resident memory CD8 T cells protecting from tumors and infection
MacKerracher, A., Sommershof, A., & Groettrup, M. (2022) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2022.106209 · Cited by 13
“In line with this, several studies have found a correlation of TRM cells numbers and the overall survival rate in various tumors (Djenidi et al., 2015; Koh et al., 2017; Komdeur et al., 2017; Marceaux et al., 2021; Zens et al., 2016).”
ResultDual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells
Christo, S. N., McDonald, K. M., Burn, T. N., Kurd, N. S., Stanfield, J., Kaneda, M. M., Seelige, R., Dillon, C. P., Fisher, T. S., Baaten, B. J. G., et al. (2024) · Clinical & Translational Immunology · doi:10.1002/cti2.70014 · Cited by 12
“17,18 These tumor-resident CD8 + TIL have been shown to remain anchored at sites of tumorigenesis where they provide rapid local protection 19,20 and have been associated with improved survival of patients with a range of solid cancers.”
Ali, A., Bari, M. F., Arshad, S., Wahid, M., Safdar, J., Anwar, K., & Farooqui, W. A. (2025) · BMC Cancer · doi:10.1186/s12885-025-13764-2 · Cited by 12
“…CD69, PD-1, CTLA-4, TIM-3, LAG-3, PD-1 [29] Skin cancers CD103, CD69, CD49a, CD39, CXCR6 [30] Lung cancer CD103 + , CD69 + , CD39 + , LFA-1, [31, 32] Cervical cancer CD103, CD69, CD49a, PD-1, Tim-3 [33] Esophageal cancer CD103, CD49a, CD69, CD39, PD-1, CTLA-4 [34] studies following methodology…”
Tissue-resident lymphocytes: weaponized sentinels at barrier surfaces
Belz, G. T., Denman, R., Seillet, C., & Jacquelot, N. (2020) · F1000Research · doi:10.12688/f1000research.25234.1 · Cited by 12
Rainey, M. A., Allen, C. T., & Craveiro, M. (2023) · Oral Oncology · doi:10.1016/j.oraloncology.2023.106570 · Cited by 12
Safi, S., Beckhove, P., Warth, A., Benner, A., Roeder, F., Rieken, S., Debus, J., Dienemann, H., Hoffmann, H., & Huber, P. E. (2015) · BMC Cancer · doi:10.1186/s12885-015-2006-2 · Cited by 12
Mechanisms of tumor immunotherapy, with a focus on thoracic cancers
Ferro, S., Huber, V., & Rivoltini, L. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.07.30 · Cited by 13
“Counting of total CD8 T cells, and not of other immune cell subsets including CD20 B cells or CD4 helper lymphocytes, was found to be associated with a higher survival rate in terms of overall survival (OS) and progression-free survival (PFS) (32), with studies by other teams validating the evidence independently (33,…”
ResultTumor microenvironment: the formation of the immune profile
Олейник, Е. К., Шибаев, М. И., Ignatiev, K. S., Олейник, В. М., & Жулай, Г. А. (2020) · Medical Immunology (Russia) · doi:10.15789/1563-0625-tmt-1909 · Cited by 12
Schmidt, A. P., Fuchs, J., Dedden, M., Kocher, K., Schülein, C., Hübner, J., Antão, A. V., Irrgang, P., Oltmanns, F., Viherlehto, V., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58931-y · Cited by 11
“In addition, CD103 expression was linked to a higher cytotoxic potential of CD8 + T cells in the context of transplant rejections 43 or different tumor models providing a better survival prognosis in the context of cancer 44,45 .”
Resident Memory T Cells in the Tumor Microenvironment
Williams, J. B., & Kupper, T. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_3 · Cited by 12
Natsuki, S., Tanaka, H., Nishiyama, M., Mori, T., Deguchi, S., Miki, Y., Yoshii, M., Tamura, T., Toyokawa, T., Lee, S., et al. (2023) · Cancer Science · doi:10.1111/cas.15750 · Cited by 11
Kammer, M. N., Mori, H., Rowe, D. J., Chen, S., Vasiukov, G., Atwater, T., Senosain, M.-F., Antic, S., Zou, Y., Chen, H., et al. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100504 · Cited by 11
Chan, R., Aphivatanasiri, C., Poon, I. K., Tsang, J. Y., Ni, Y., Lacambra, M. D., Li, J. J. X., Lee, C., & Tse, G. M.-K. (2023) · The Oncologist · doi:10.1093/oncolo/oyad199 · Cited by 11
To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors
Mondino, A., & Manzo, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01915 · Cited by 14
Xia, T., Meng, L., Zhao, Z., Li, Y., Wen, H., Sun, H., Zhang, T., Wei, J., Li, F., & Liu, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02347-3 · Cited by 11
Cortinovis, D. L., Canova, S., Abbate, M., Colonese, F., & Bidoli, P. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00067 · Cited by 11
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.